Safety Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke

Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of Lu AA24493 in Acute Ischemic Stroke

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00756249

Enrollment

Registered

2008-09-22

Start date

2007-10-31

Completion date

2008-12-31

Last updated

2010-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Keywords

Acute ischemic stroke, Erythropoietin, Carbamylated, Neuroprotection

Brief summary

The primary purpose of the study is to determine whether carbamylated erythropoietin (CEPO) is a safe treatment for patients who have suffered an acute ischemic stroke.

Detailed description

Acute ischemic stroke is a major cause of death and severe disability. There is only one approved pharmacological treatment, Alteplase, which has to be administered within 3 hours from symptom onset. Consequently, only about 2-3% of patients world wide with ischemic strokes are treated. The naturally occurring hormone, erythropoietin (EPO), is able to protect various neuronal tissues from ischemic injury and is beneficial in animal models of acute ischemic stroke. However, treatment of stroke with EPO is undesirable due to its ability to stimulate production of red blood cells and to promote the blood to coagulate. Lu AA24493 is a modified (carbamylated) version of EPO, neuroprotective but without the haematopoietic side effects. Lu AA24493 is developed for treatment of patients with acute ischemic stroke. In this safety study of single doses with Lu AA24493, patients will receive Lu AA24493 within 12-48 hours from symptom onset.

Interventions

DRUGLu AA24493 (CEPO)

0.005 - 50.0 mcg/kg body weight, IV, within 12-48 hrs from symptom onset

DRUGPlacebo

Vials with solution for IV infusion

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

50 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Age between 50 and 90 years * Clinical diagnosis of acute ischemic stroke * Measurable stroke-related deficit * Patient is stable * Treatment can be initiated between 12 hours and 48 hours after the onset of stroke * Expected hospital stay of at least 72 hours after study medication * If female then not of childbearing potential

Exclusion criteria

* Primary intracerebral haemorrhage (ICH), or parenchymal haemorrhagic transformation of infarction (type PHI or PHII as defined in ECASS), subarachnoid haemorrhage (SAH), arterio-venous malformation (AVM), cerebral aneurysm, or cerebral neoplasm * Treated with a thrombolytic \<24 hours (if \>24 hours excluded ICH then eligible) * Score \>0 on the NIHSS item 1a * Pre-stroke mRS score \>1 * Uncontrolled hypertension * Previous treatment with erythropoietin * Clinically significant abnormal ECG * Cerebral pathology * Received or donated blood within previous 3 months

Design outcomes

Primary

Measure	Time frame
National Institutes of Health Stroke Scale (NIHSS) and the modified Rankin Scale (mRS)	Baseline, Day 7, Day 30; for NIHSS also Day 2 and 3

Secondary

Measure	Time frame
Pharmacokinetics, immunogenicity and mechanistic biomarkers (S-100b, glial fibrillary acidic protein (GFAP), matrix metalloproteinase 9 (MMP-9))	Baseline, Day 1-4, Day 7 and Day 30

Countries

Finland, France, Netherlands, Singapore, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026